Bioinformatics Analysis in R

Advanced Gene Expression: Analysis of Cancer Genome Atlas

Ivan G. Costa, Martin Grasshoff

Institute for Computational Genomics RWTH University Hospital www.costalab.org



Summary

- 1. Obtain data from cancer patients from TCGA
- 2. Pre-process and analysis of RNA-seq data
- 3. Use machine learning to build a classifier for personalised medicine
- 4. Use interesting markers for survival analysis




The Cancer Genome Atlas

- TCGA is a NCI (US) funded project to generate cohorts of cancers:
 - -Currently 33 cancers with 80-780 patients
- Comprehensive data from tissues:
 - Histology, clinical, gene expression profiling, copy number variation, DNA methylation using arrays or sequencing
- Data is publicly available upon generation and deposited in a portal (<u>portal.gdc.cancer.gov</u>)




The Cancer Genome Atlas - Portal






The Cancer Genome Atlas - Portal




Check a gene or cancer type! I will try liver











Gene expression data!




















Practical part not covered!








Next Generation Sequencing

- NGS take advantage of parallelization
 - reads millions/billions of reads per run
 - short reads (50-100 bps)
 - error rates (0.1-1%)






Read Types



Single end

Paired end Ins: 200-800 bp









Alignment

- a large reference sequence is given (genome)
 - up to billions of base pairs
- short reads (<200bps)
- find most probable position of the read in the genome (by inexact string matching)






Alignment - Split Read Mapping (RNA-Seq)



Alignment - Split Read Mapping (RNA-Seq)



- reads are split between exons when mapped to genome
- aligners use transcript information or try to find splice events (STAR & TOPHAT)




Reference based aligners - Overview

	Time	Precision	Pairs	GAPs	Phred	Memory	Application (Comments)
BOWTIE	+		+	-	-	5GB	General (max. 3 missmatches)
BWA	+		+	+	+	8GB	General (max of 200bps reads)
NOVOALIGN		+	+	+	+	8GB	General
							(commercial license)
STAR	+		+	-	+	32GB	RNA-Seq (allow split-maps)
BISMARK	+		+	+	+	10GB	Bisulfite/reduced
							sequencing

Computers need large memory and a few hours of computation per experiment!

Quantification (Count Matrix)



Simple Counting Approaches

Gene Level - 17 reads

Exon level - exon 1 (8 reads), exon 2 (3 reads), exon 3 (6 reads)

Transcript Level - Exons 1,2 & 3 (10 reads) and exon 1 & 3 (7 reads) *

* complex computational methods required (RSe, or TopHAT needed for this)


Fragments per Kilobase (FPKM)

- normalize counts by read size (kb) and RNA-seq library size (mb)




RNA-seq and Differential Analysis

Arrays and RNA-seq have distinct distributions



VOOM analysis is necessary to make variance similar to arrays.





Institute for

Computational Genomics

Personalized Medicine


Diagnosis and treatment choices is mostly carried on macromolecular features:

- morphology of tumours (image), symptoms, blood levels

Challenges: use molecular markers (expression or genetics) for diagnosis or treatment selection.



Machine Learning - Classifier




Data

Expression matrix X (genes vs samples) classification vector *Y* (diagnosis)

Find a function:

$$f(x) \rightarrow y$$

Machine Learning - Classifier



Data

Expression matrix X (genes vs samples) classification vector Y (diagnosis)

Find a function:


$$f(x) \rightarrow y$$

For new patients X':

$$f(x') \rightarrow y'$$



Linear Classifier



Linear Function:


$$f(x, A) = a_0 + a_1 x_1 + ... + a_L x_L$$

 $f(x, A) > 0 \Rightarrow \text{class A}$
 $f(x, A) \le 0 \Rightarrow \text{class B}$

- Works for 2 classes only
 - Train a function for each cancer type
- Find coefficients A
 - estimated with neural networks or support vector machines




Linear Classifier - Problems



- Most real world problems are not linearly separable!
- There will be always some error!
- Solution: non-linear functions

Nonlinear Classifier - Problems



Polinomial Function


$$f(x, A) = a_0 + a_{11}x_{11}^3 + \dots + a_{L1}x_{L}^3$$
$$a_{12}x_{11}^2 + \dots + a_{L2}x_{L}^2$$
$$a_{12}x_{11}^2 + \dots + a_{L2}x_{L}^3$$

Third order polynomial

Problem: overfitting



Nonlinear Classifier - Problems



Polinomial Function


$$f(x, A) = a_0 + a_{11}x_{11}^3 + \dots + a_{L1}x_{L}^3$$
$$a_{12}x_{11}^2 + \dots + a_{L2}x_{L}^2$$
$$a_{12}x_{11}^2 + \dots + a_{L2}x_{L}^3$$

Third order polynomial

Problem: overfitting



Nonlinear Classifier - Problems



Polinomial Function

$$f(x, A) = a_0 + a_{11}x_{1}^3 + \dots + a_{L1}x_{L}^3$$

$$a_{12}x_{1}^2 + \dots + a_{L2}x_{L}^2$$

$$a_{12}x_{1} + \dots + a_{L2}x_{L}$$

Third order polynomial

Problem: overfitting




Curse of Dimensionality

Size of a Euclidean space grows with dimension (number of genes)

Dots (patients) are sparsely distributed in space






Sparse data

- three genes
- 2 patients with known cancer (red vs yellow)
- 1 unknown (green)






- Sparse data
 - three genes
 - 2 patients with known cancer (red vs yellow)
 - 1 unknown (green)

Perfect classifier (on training)






- Sparse data
 - three genes
 - 2 patients with known cancer (red vs yellow)
 - 1 unknown (green)

Both are perfect classifiers (on training)

Hard to generalise!





There are millions of perfect linear classifiers

And even more nonlinear classifiers!




Dealing with Curse of Dimensionality

- Have a proper training / test evaluation procedure
- Use classifiers which are as simple as possible
- Reduce the dimension of your data (feature selection or PCA)




Measures for a two class problem (cancer + vs. non-cancer -)






Measures for a two class problem (cancer + vs. non-cancer -)



Source: Lever et al., Nat. Methods (2016)




- The performance of your classifier needs to be evaluated on your test data:
 - an independent "validation cohort"
 - or retain a set of samples (1/3) that has similar distribution of classes of your total data






- The performance of your classifier needs to be evaluated on your test data:
 - an independent "validation cohort"
 - or retain a set of samples (1/3) that has similar distribution of classes of your total data



- Never use test data to improve classification (choose a better classifier or marker gene)
 - For this you need to establish validation data (or cross validation)

 Institute for Computational Genomics
 Computational Genomics

Cross-validation



Elastic Net

Is based on a linear function:

$$f(x, A) = a_0 + a_1 x_1 + ... + a_L x_L$$

 $f(x, A) > 0 \Rightarrow \text{classe A}$
 $f(x, A) \le 0 \Rightarrow \text{classe B}$

- Find coefficients *A, while most of then have* 0.
 - A shrinkage factor (λ) controls the number of genes selected.
 - Shrinkage factor can be automatically identified with cross-validation.



Hands on!



Exercise (after the handout)

You should perform clustering of tissues with liver cancer. Tip: use code similar to the one seen in gene expression data (day 3). Since, we are interested in grouping patients, you can transpose the matrix with the function **t**.

- 1. Can you see nice clusters in the dendrogram?
- 2. What about genes associated to each group? Are they associated to some particular biological function? Use differential expression analysis and GO enrichment analysis to solve this task.



Survival Analysis

Can be used to evaluate if characteristics of a patient indicate an increase/decrease risk of survival

- clinical: tumour type, gender
- Molecular: expression of a gene, mutation

Common Survival Tests:

- Cox proportional hazards regression (not seen here)
 - Compares survival with a numeric variable
- Kaplan-Meier graph / Log-rank test
 - compares the survival of groups of individuals



Kaplan-Meier graph / Log-rank test

Data:

- Event: dead / alive


- **Time**: period between first and last observation.

- Characteristics: sex, tumor grade

Patient	Status	Time	Sex
1	Dead	343	Male
2	Alive	20	Male
3	Alive	300	Female
4	Dead	200	Male




Survival of LIHC patients - male vs. Female





Survival of LIHC patients - male vs. Female




Probability (X days) = # cases alive after X days # cases measured after X days



Log-rank test


Is the survival difference significant?







Log-rank test

Is the survival difference significant?










Kaplan-Meier / Log-Rank Test

KM and LRT can compare several groups at a time.

Survival vs Tumour stage at diagnosis



Survival Analysis and Biological Markers

How to perform survival analysis on biological markers?

- 1. Given their continuous nature of gene expression, Cox hazards test is recommended.
- 2. An alternative is to group patients by expression of a gene (low/high expression) and use Kaplan-Meyer plots (seen in practical).

Important: if you test several markers you need to correct for multiple testing!!!

Hands on!

